866-997-4948 (US-Canada Toll Free)

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

Published By :

GBI Research

Published Date : 2013-09-23

Category :

Pharmaceutical

No. of Pages : N/A

Product Synopsis

GBI Research, the leading business intelligence provider, has released its latest research: Solid Tumors in Asia-Pacific Market to 2019 - New and Anticipated Approvals of Targeted Therapies to Trigger a Shift in Treatment Paradigm, which provides in-depth analysis of four key therapeutic indications within the Asia-Pacific (APAC) solid tumors market – bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer – covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these four solid tumor types.  The value... Read More

Table Of Content

Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Solid Tumors Market in Asia Pacific to 2019 - Introduction
2.1 Introduction

3 Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape
3.1 Bladder Cancer
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 Diagnosis
3.1.5 Classification
3.1.6 Epidemiology
3.1.7 Prognosis and Disease Staging
3.1.8 Treatment Options
3.2 Ovarian Cancer
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 Diagnosis
3.2.5 Classification
3.2.6 Epidemiology
3.2.7 Prognosis and Disease Staging
3.2.8 Treatment Options
3.3 Pancreatic Cancer
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 Diagnosis
3.3.5 Classification
3.3.6 Epidemiology
3.3.7 Prognosis and Disease Staging
3.3.8 Treatment Algorithm
3.4 Prostate Cancer
3.4.1 Symptoms
3.4.2 Etiology
3.4.3 Pathophysiology
3.4.4 Co-Morbidities and Complications
3.4.5 Diagnosis
3.4.6 Classification
3.4.7 Epidemiology
3.4.8 Prognosis and Disease Staging
3.4.9 Treatment Options

4 Solid Tumors Market in Asia Pacific to 2019 - Marketed Products
4.1 Bladder Cancer
4.2 Ovarian Cancer
4.3 Pancreatic Cancer
4.4 Prostate Cancer
4.5 Key Marketed Products
4.5.1 Carboplatin
4.5.2 Cisplatin
4.5.3 Gemcitabine
4.5.4 Paclitaxel
4.5.5 Doxorubicin
4.5.6 Avastin (bevacizumab)
4.5.7 Tarceva (erlotinib)
4.5.8 Sutent (sunitinib)
4.5.9 Afinitor (everolimus)
4.5.10 Taxotere (docetaxel)
4.5.11 Zytiga (abiraterone acetate)
4.5.12 Jevtana (cabazitaxel)

5 Solid Tumors Market in Asia Pacific to 2019 - Pipeline Analysis
5.1 Bladder Cancer Pipeline
5.1.1 Overall Pipeline
5.1.2 Pipeline Analysis by Molecule Type
5.1.3 Pipeline Analysis by Mechanism of Action
5.2 Ovarian Cancer Pipeline
5.2.1 Overall Pipeline
5.2.2 Pipeline Analysis by Molecule Type
5.2.3 Pipeline Analysis by Mechanism of Action
5.3 Pancreatic Cancer Pipeline
5.3.1 Overall Pipeline
5.3.2 Pipeline Analysis by Molecule Type
5.3.3 Pipeline Analysis by Mechanism of Action
5.4 Prostate Cancer Pipeline
5.4.1 Overall Pipeline
5.4.2 Pipeline Analysis by Molecule Type
5.4.3 Pipeline Analysis by Mechanism of Action
5.5 Promising Drug Candidates in the Pipeline
5.5.1 Abraxane (albumin-bound paclitaxel)
5.5.2 AMG 386 (trebananib)
5.5.3 Votrient (pazopanib)
5.5.4 Xtandi (enzalutamide)

6 Solid Tumors Market in Asia Pacific to 2019- Market Forecast
6.1 Asia-Pacific Market
6.1.1 Treatment Usage Patterns
6.1.2 Annual Cost of Treatment
6.1.3 Market Size
6.2 India
6.2.1 Treatment Usage Patterns
6.2.2 Annual Cost of Treatment
6.2.3 Market Size
6.3 Australia
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Treatment
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Treatment
6.4.3 Market Size
6.5 Japan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Treatment
6.5.3 Market Size
6.6 Drivers and Barriers for the Solid Tumors Market in APAC
6.6.1 Drivers
6.6.2 Barriers

7 Solid Tumors Market in Asia Pacific to 2019 - Deals and Strategic Consolidations
7.1 Deals Analysis
7.2 Major Co-Development Deals
7.2.1 ScinoPharm Taiwan and Coland Enter into Agreement to Develop Generic Oncological Drugs
7.2.2 Bind Biosciences Enters into Agreement with Amgen to Develop Cancer Drugs
7.2.3 Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug
7.2.4 Merck Serono Enters into Co-Development Agreement with Threshold Pharma for TH-302,
Pancreatic Cancer Drug
7.2.5 Seattle Genetics Exercises Option for Co-Development Agreement with Agensys (affiliate of
Astellas) for ASG-15ME
7.3 Major Licensing Deals
7.3.1 Spectrum Pharma Amends Licensing Agreement with Allergan for Apaziquone
7.3.2 Chugai Pharma Enters Into Licensing Agreement with Debiopharm Group for FF284
7.3.3 Baxter International Enters into Licensing Agreement with Onconova Therapeutics for
Rigosertib
7.3.4 Dyax Enters Into Licensing Agreement with Kadmon for Oncology Drug
7.3.5 Medigene Extends Licensing Agreement with Syncore for EndoTAG-1

8 Solid Tumors Market in Asia Pacific to 2019 - Appendix
8.1 Pipeline Drugs by Phase
8.1.1 Phase III
8.1.2 Pre-registration/NDA-filed
8.2 Market Forecasts to 2018
8.2.1 APAC
8.2.2 Australia
8.2.3 China
8.2.4 India
8.2.5 Japan
8.3 Market Definitions
8.4 Abbreviations
8.5 Sources
8.6 Research Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Primary Research
8.6.4 Therapeutic Landscape
8.6.5 Geographical Landscape
8.6.6 Pipeline Analysis
8.7 Expert Panel Validation
8.8 Contact Us
8.9 Disclaimer

List of Tables


Table 1: Solid Tumors Market, Bladder Cancer, AJCC TNM Staging System, 2010
Table 2: Solid Tumors Market, Bladder Cancer, Treatment by Staging, 2013
Table 3: Solid Tumors Market, Ovarian Cancer, AJCC’s TNM and FIGO Staging Systems, 2013
Table 4: Solid Tumors Market, Pancreatic Cancer, AJCC TNM Staging System, 2013
Table 5: Solid Tumors Market, Prostate Cancer, AJCC Staging System, 2013
Table 6: Solid Tumors Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 7: Solid Tumors Market, Global, Pharmaceutical Pipeline (Pre-registration/NDA-filed), 2013
Table 8: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Market Forecast, 2012–2019
Table 9: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Market Forecast, 2012–2019
Table 10: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Market Forecast, 2012–2019
Table 11: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Market Forecast, 2012–2019
Table 12: Solid Tumors Market, Australia, Ovarian Cancer, Market Forecast, 2012–2019
Table 13: Solid Tumors Market, Australia, Bladder Cancer, Market Forecast, 2012–2019
Table 14: Solid Tumors Market, Australia, Pancreatic Cancer, Market Forecast, 2012–2019
Table 15: Solid Tumors Market, Australia, Prostate Cancer, Market Forecast, 2012–2019
Table 16: Solid Tumors Market, China, Ovarian Cancer, Market Forecast, 2012–2019
Table 17: Solid Tumors Market, China, Bladder Cancer, Market Forecast, 2012–2019
Table 18: Solid Tumors Market, China, Pancreatic Cancer, Market Forecast, 2012–2019
Table 19: Solid Tumors Market, China, Prostate Cancer, Market Forecast, 2012–2019
Table 20: Solid Tumors Market, India, Ovarian Cancer, Market Forecast, 2012–2019
Table 21: Solid Tumors Market, India, Bladder Cancer, Market Forecast, 2012–2019
Table 22: Solid Tumors Market, India, Pancreatic Cancer, Market Forecast, 2012–2019
Table 23: Solid Tumors Market, India, Prostate Cancer, Market Forecast, 2012–2019
Table 24: Solid Tumors Market, Japan, Ovarian Cancer, Market Forecast, 2012–2019
Table 25: Solid Tumors Market, Japan, Bladder Cancer, Market Forecast, 2012–2019
Table 26: Solid Tumors Market, Japan, Pancreatic Cancer, Market Forecast, 2012–2019
Table 27: Solid Tumors Market, Japan, Prostate Cancer, Market Forecast, 2012–2019

List of Figures


Figure 1: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Epidemiology, 2012–2019
Figure 2: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Superficial and Stage I, 2013
Figure 3: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Stage II and III, 2013
Figure 4: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Epidemiology, 2012–2019
Figure 5: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage I and II, 2013
Figure 6: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage III and IV, 2013
Figure 7: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Epidemiology, 2012–2019
Figure 8: Solid Tumors Market, Pancreatic Cancer, Treatment Algorithm, 2013
Figure 9: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Epidemiology, 2012–2019
Figure 10: Solid Tumors Market, Prostate Cancer, Treatment Algorithm, 2013
Figure 11: Solid Tumors Market, Global, Avastin, Annual Sales ($m), 2006–2013e
Figure 12: Solid Tumors Market, Global, Tarceva, Annual Sales ($m), 2006–2013e
Figure 13: Solid Tumors Market, Global, Sutent, Annual Sales ($m), 2006–2013e
Figure 14: Solid Tumors Market, Global, Afinitor, Annual Sales ($m), 2009–2013e
Figure 15: Solid Tumors Market, Global, Zytiga, Annual Sales ($m), 2011–2013e
Figure 16: Solid Tumors Market, Global, Jevtana, Annual Sales ($m), 2010–2013e
Figure 17: Solid Tumors Market, Global, Bladder Cancer, Pipeline, 2013
Figure 18: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Molecule Type, 2013
Figure 19: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Mechanism of Action, 2013
Figure 20: Solid Tumors Market, Global, Ovarian Cancer, Pipeline, 2013
Figure 21: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Molecule Type, 2013
Figure 22: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Mechanism of Action, 2013
Figure 23: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline, 2013
Figure 24: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Molecule Type, 2013
Figure 25: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Mechanism of Action, 2013
Figure 26: Solid Tumors Market, Global, Prostate Cancer, Pipeline, 2013
Figure 27: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Molecule Type, 2013
Figure 28: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Mechanism of Action, 2013
Figure 29: Solid Tumors Market, Asia-Pacific, Market Size ($m), 2012–2019
Figure 30: Solid Tumors Market, India, Market Size ($m), 2012–2019
Figure 31: Solid Tumors Market, Australia, Market Size ($m), 2012–2019
Figure 32: Solid Tumors Market, China, Market Size ($m), 2012–2019
Figure 33: Solid Tumors Market, Japan, Market Size ($m), 2012–2019
Figure 34: Solid Tumors Market, Global, Deals, 2006–2013
Figure 35: Solid Tumors Market, Global, Co-development Deals, 2006–2013
Figure 36: Solid Tumors Market, Global, Licensing Deals, 2006-2013
Figure 37: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

Full Name * Message
Your Email *
Job Title
Phone No. * (Pls. Affix Country Code) Security Code *

Upcoming Reports

  • Vaccine Production Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecasts 2012 - 2018

    By - Transparency

    High growth rate in emerging markets, technological advancements, strong support from governments and other active associations like WHO and GAVI, and increased investment in research and development are all leading to the overall growth of the vaccine production market. The vaccine production market is expected to exhibit improved performance in the coming years due to the successful launch of new vaccines.  Vaccines for different illnesses are among the top revenue earners in the pharmaceutical industry. Research and development in this field is leading to the...

  • Wheelchair Accessible Vehicle Converters Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

    By - Transparency

    Vehicles which are converted in a way that have easy access for wheelchairs are termed as wheelchair accessible vehicles or WAV’s. The vehicles are specially converted from a standard vehicle to WAV in order to accommodate the wheelchair. Wheelchair accessible vehicles are considered as multipurpose vehicle as it can be used for medical as well as general purpose. The important aspect of wheelchair accessible vehicle is that patient can travel while remaining in their wheelchair, either as a passenger or driver. The common feature that are associated with most of the wheelchair...

  • Greece: prepared or preserved fish market

    By - Williams and Marshal Strategy

    This report presents a comprehensive overview of the prepared or preserved fish market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the prepared or preserved fish market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents...